Kairos Pharma Ltd (KAPA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | |
| Cash Flows From Operating Activities | ||||
| Net Income | -5,447 | -2,603 | -1,812 | -1,050 |
| Depreciation Amortization | 2,330 | 314 | 216 | 568 |
| Accounts receivable | N/A | -2,358 | N/A | N/A |
| Accounts payable and accrued liabilities | -793 | 404 | 772 | 129 |
| Other Working Capital | -806 | -1,984 | 764 | 129 |
| Other Operating Activity | 1,275 | 2,272 | 141 | -129 |
| Operating Cash Flow | $-3,441 | $-3,955 | $81 | $-353 |
| Cash Flows From Investing Activities | ||||
| Investing Cash Flow | $N/A | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | ||||
| Change In Short Term Borrowing | N/A | 142 | N/A | 925 |
| Debt Issued | 3,602 | N/A | N/A | N/A |
| Debt Repayment | N/A | N/A | N/A | -10 |
| Common Stock Issued | 3,058 | 5,524 | 0 | N/A |
| Other Financing Activity | 0 | -532 | -425 | -198 |
| Financing Cash Flow | $6,660 | $5,134 | $-425 | $717 |
| Beginning Cash Position | 1,272 | 93 | 437 | 73 |
| End Cash Position | 4,491 | 1,272 | 93 | 437 |
| Net Cash Flow | $3,219 | $1,179 | $-344 | $364 |
| Free Cash Flow | ||||
| Operating Cash Flow | -3,441 | -3,955 | 81 | -353 |
| Free Cash Flow | -3,441 | -3,955 | 81 | -353 |